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Short report
Smoking cessation in severe mental
illness: combined long-term quit rates
from the UK SCIMITAR trials programme
Simon Gilbody, Emily Peckham, Della Bailey, Catherine Arundel, Paul Heron, Suzanne Crosland,
Caroline Fairhurst, Catherine Hewitt, Jinshuo Li and members of the SCIMITAR+ collaborative*
Summary
Smoking contributes to health inequalities for people with severe
mental illness (SMI). Although smoking cessation interventions
are effective in the short term, there are few long-term trial-
based estimates of abstinence. The SCIMITAR trials programme
includes the largest trial to date of a smoking cessation inter-
vention for people with SMI, but this was underpowered to
detect anticipated long-term quit rates. By pooling pilot and full-
trial data we found that quit rates were maintained at 12 months
(OR = 1.67, 95% CI 1.02–2.73, P = 0.04). Policymakers can now be
confident that bespoke smoking cessation interventions pro-
duce successful short- and long-term quitting.
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Life expectancy among people with severe mental illnesses (SMIs)
such as schizophrenia and bipolar disorder is reduced by around
20 years.1 Smoking contributes to this profound health inequality
and remains one of the most important modifiable risk factors
for early death and poor physical health.2 Although the rates of
smoking are falling for most sections of the population, the preva-
lence of smoking remains at around 50% for people with severe
mental ill health.3 Recent policy initiatives (including the 2019
NHS Long Term Plan: https://www.longtermplan.nhs.uk/) identify
smoking cessation for people with SMI as a priority, but there
remains uncertainty about how mental health services should
deliver smoking cessation interventions.
The UK Smoking Cessation Trials for Severe Mental Ill Health
programme was commissioned sequentially in 2009 and 2013 by the
UK National Institute for Health Research (NIHR). The trials pro-
gramme followed the Medical Research Council’s complex inter-
ventions framework,4 by first designing a combined behavioural
and pharmacological intervention specifically for people with
SMI – the Smoking Cessation Intervention for People with Severe
Mental Ill Health (SCIMITAR) – and then undertaking a pilot
trial (SCIMITAR),5 before embarking on a full-scale randomised
controlled trial (RCT) (SCIMITAR+) to determine clinical and
cost-effectiveness.6
Policymakers find precise longer-term estimates of quitting to
be helpful, but the research literature is dominated by small
sample sizes and short-term follow-up.7 The SCIMITAR+ trial
is the largest trial of smoking cessation in SMI to date, and has
demonstrated the success of smoking cessation programmes in
the short term (6 months).6 However, the SCIMITAR+ trial still
lacked sufficient power to detect the expected differences in the
prespecified primary outcome and might have failed to detect
anticipated differences in long-term outcomes (making a type 2
error). In this short report we combine pilot and full-trial data
to maximise the power and precision of long-term estimates of
smoking cessation.
Method
The design, methods and analysis of the SCIMITAR pilot
and SCIMITAR+ trials were registered in the public domain
(ISRCTN79497236 and ISRCTN72955454) and have been published
elsewhere.5,6 Briefly, the pragmatic SCIMITAR trials tested the effect-
iveness of a manualised combined behavioural and pharmacological
intervention for people with SMI who smoked, compared with usual
care. Participants received face-to-face behavioural support delivered
by a mental health professional and were prescribed quit-smoking
medication according to patient choice from a range of medications
recommended by the National Centre for Smoking Cessation
Training (NCSCT).8 Participants mostly chose nicotine replacement
as their pharmacological support.
The prespecified primary outcome for both trials was biologic-
ally verified 7-day point prevalence abstinence at 12 months post-
randomisation (defined as self-reported no smoking in the previous
7 days and an expired carbon monoxide (CO) level of <10 ppm).
The SCIMITAR pilot study included 97 participants and the full
trial included 526. The SCIMITAR+ full RCT was powered at
80% to detect a relative increase in quitting of 1.7 (an effect size
derived from the pilot trial and from our systematic reviews in
this area9), assuming a control quit rate of 20%, equal randomisa-
tion and a two-sided alpha of 0.05. Allowing for 20% loss to
follow-up at 12 months required a total of 393 participants to be
recruited and randomised. In the final trial, this sample size was
exceeded but the control event rate (10%) was lower than antici-
pated, meaning that statistical power was substantially reduced
(post hoc power estimated at 35%).
In view of the mirror design (including primary end-point) we
maximised precision and power to estimate the 12-month outcome
by utilising a post hoc meta-analysis to combine the randomised
data from both trials in RevMan 5 for Windows. We pooled the
primary end-point of both trials using a fixed effects model of
dichotomous outcomes (7 day quitting versus smoking). We
calculated the pooled estimates of unadjusted quit rates using
Mantel–Haenszel odds ratios (ORs) and 95% confidence intervals
(CIs), and also pooled estimates of risk difference. We made the
most conservative estimate by assuming that all participants
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without a 12-month CO measurement were still smokers. In each
trial an odds ratio that adjusted for baseline differences in
smoking severity had also been reported as the primary outcome,
in line with a prespecified data analysis plan. We therefore con-
ducted a sensitivity analysis by meta-analysing adjusted estimates
using the inverse variance method.
Results
The combined sample size of the pilot and full SCIMITAR trials was
623, comprising participants with schizophrenia or bipolar dis-
order. The combined odds ratio of successful quitting was in line
with our prespecified estimate and favoured the bespoke SMI
smoking cessation intervention (OR = 1.67, 95% CI 1.02–2.73,
P = 0.04) with no between-study heterogeneity (I2 = 0). Fig. 1
shows a forest plot of 12-month outcomes. The pooled absolute
reduction in smoking rate at 12 months was 5.0% (95% CI
0.0–10.0%). A sensitivity analysis utilising adjusted estimates pro-
duced a largely consistent pooled odds ratio (OR = 1.76, 95% CI
1.05–2.96, P = 0.03).
Discussion
The SCIMITAR trials programme measured long-term quit rates at
12 months using a biologically verified measure of abstinence, but
was still underpowered to detect our prespecified estimate despite
having planned the sample size in a pilot trial using conventional
parameter estimates (80% power, P < 0.05, two-sided test). By
using the opportunity to pool RCT data drawn from both pilot
and trial data, the power and precision of estimates has been max-
imised. Ourmain finding is that bespoke smoking cessation resulted
in a demonstrable effect at 12months that we were not able to detect
in analysis of single trials. The results of this pooled analysis present
convincing evidence drawn from pragmatic trials of the impact of a
bespoke intervention designed for people with SMI, and this can be
used to formulate policy in this area.
Pilot trials are often used to derive estimates of recruitment and
retention in evaluating novel interventions, but also in planning
sample size calculations for fully powered trials.10 The pilot trial
of the bespoke smoking cessation intervention6 did not correctly
predict the baseline event rate and as a result the SCIMITAR+
trial was underpowered to detect our prespecified estimate of suc-
cessful quitting. The present analysis utilises all trial-based data
and represents an additional use of internal pilot-trial data. On
the basis of these pooled data, the combined pharmacological and
behavioural approach in SCIMITAR forms a candidate intervention
to reduce historically elevated smoking rates among people with
SMI.11 The challenge is the implementation of research evidence
in mental health services to ensure that effective treatments are
offered as a matter of routine.
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Fig. 1 Combined 12-month abstinence, from SCIMITAR pilot and full-trial data.
M-H, Mantel–Haenszel; UC, usual care; BSC, bespoke smoking cessation.
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